High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma

• Príomhchruthaitheoirí: Harsimran Kaur Garcha (Údar), Nabanita Nawar (Údar), Helena Sorger (Údar), Fettah Erdogan (Údar), Myint Myat Khine Aung (Údar), Abootaleb Sedighi (Údar), Pimyupa Manaswiyoungkul (Údar), Hyuk-Soo Seo (Údar), Susann Schönefeldt (Údar), Daniel Pölöske (Údar), Sirano Dhe-Paganon (Údar), Heidi A. Neubauer (Údar), Satu M. Mustjoki (Údar), Marco Herling (Údar), Elvin D. de Araujo (Údar), Richard Moriggl (Údar), Patrick T. Gunning (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2022-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, inc...